Skip to main content

Immunology

UTSW Rheum Grand Rounds - IgG4 Dz - Plasmablasts may be a useful biomarker; but is not generally available in clinical labs (must be done on fresh whole blood) @UTSWIMchief https://t.co/GlEKw0KD3O
Dr. John Cush RheumNow ( View Tweet)
Jan 21, 2021
New Download Available on COVID-19 & mRNA Vaccines https://t.co/mvmn17Fl3B https://t.co/ceICzbDZi5
Dr. John Cush RheumNow ( View Tweet)
Jan 17, 2021

2020 Rheumatology Year in Review

Jan 14, 2021

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related. Below, are our top news items

Read Article

ProDERM Study: IVIG in Dermatomyositis

Jan 13, 2021

The ProDERM study design and outcomes are previewed in Medicine; and as promised the results were revealed at ACR Convergence in November 2020 showing that IVIg is safe, effective and superior to placebo i(PBO) in patients with dermatomyositis (DM).

Read Article

Adipose Transplants as a New Regulator of Osteoarthritis

Jan 11, 2021

A novel report from PNAS suggests that in osteoarthritis (OA), the damage is not entirely from body weight and mechanics, instead it may be from adipose tissue itself.

Read Article

Best of 2020: ACR 2020 Reproductive Guidelines - Contraception & Counseling

Dec 29, 2020

The American College of Rheumatology established a guidelines committee that consisted of both patients, rheumatologists and maternal-fetal health experts. After a a systematic review of the medical literature regarding contraception, assisted reproductive technology, fertility preservation,

Read Article

Benlysta First Agent Approved for Lupus Nephritis

Dec 17, 2020

After the successful completion of the BLISS-LN trial and previewing the results at EULAR 2020 and ACR Convergence, GlaxoSmithKline announced yesterday that the FDA has approved belimumab (Benlysta) for use in adults with active lupus nephritis (LN) receiving background/standard therapy.

Read Article
#BestACR20Tweets RT @RichardPAConway : Dr Kaellmark reports on immunogenicity of adjuvant herpes zoster subunit vaccine in RA patients treated with JAKi. 40 RA patients and 20 controls. Satisfactory serological responses and tolerability seen. @rheumnow #ACR20 Abstr#1997 https://t.co/TR9IS9hUgu
Dr. John Cush RheumNow ( View Tweet)
Dec 07, 2020
Check on Pneumococcal Vaccination: Dr. Janet Pope ( @Janetbirdope) #ACR20 https://t.co/D9EQ3Tl2Ot https://t.co/Zn8IVorCcs
Dr. John Cush RheumNow ( View Tweet)
Dec 01, 2020
#BestACR20Tweets RT @RADoctor: Adjuvant #herpeszoster vaccine (Shingrix) not effective for 25% of JAKi-treated RA pts (n=40) for antibody response (T cell response usually worse, not reported). Is better than nothing good enough? Maybe we need to hold JAKi briefly?

Dr. John Cush RheumNow ( View Tweet)

Nov 30, 2020
Vaccination with Shingrix: Does it work for patients on JAKi? #ACR20 https://t.co/PLWn3SshcI https://t.co/APBcfP1zlH
Dr. John Cush RheumNow ( View Tweet)
Nov 25, 2020

Vaccination with Shingrix: Does it work for patients on JAKi?

Dr. Jeffrey Curtis examines abstracts #1997 and #0452 presented at the ACR 2020 annual meeting.

Read Article
Great read! "The Vaccine Review Process and Why You Should Know It" by Dr. Rachel Tate ( @uptoTate) https://t.co/l39qH3LuXm https://t.co/PR1AaQCD7V
Dr. John Cush RheumNow ( View Tweet)
Nov 19, 2020

Flu and Tofacitinib

Nov 19, 2020

Dr. Kathryn Dao reviews abstract L04 - Influenza Adverse Events in Patients with Rheumatoid Arthritis in the Tofacitinib Clinical Program - at the 2020 ACR annual meeting.

Read Article

The Vaccine Review Process and why you should know it

Nov 16, 2020

There is much controversy regarding vaccine safety and efficacy in the United States. Prior to COVID19, there were populations who lacked confidence in vaccination for any number of reasons. Dr. Grace Lee presented a great overview of the vaccination recommendation to adoption framework that

Read Article

COVID and Rheumatic Disease Patients: Dr. Kevin Winthrop

Portland-based Dr. Kevin Winthrop from OHSU discusses Saturday ACR 2020 posters #0623 and #0629 related to COVID-19 and rheumatic disease patients.

Read Article

ACR20 - Day 4 Report

Nov 12, 2020

Here are my highlights from day four, Monday, of the ACR 2020 Convergence. 



Vaccine Immunogenicity with Tofacitinib

Read Article
New podcast out now on our site #ACR20 Mid-Meeting Recap: Psoriatic Arthritis, Gout Patient Outcomes on Low-Dose Steroids, Giant Cell Arteritis Panel Vaccination w/ Shingrix: Does it work for patients on JAKi? Is it safe? https://t.co/roc1Qjec5R https://t.co/gSkkj2Kl0m
Dr. John Cush RheumNow ( View Tweet)
Nov 11, 2020
📌 #ACR20 Checkpoint Inhibitors: Past, Present and Future 👉close surveillance ➡️ early detection of iRAEs➡️ early treatment➡️ reversibility or ⬇️severity #ACRAmbassador https://t.co/AM2mfYmAtI
Elizabeth Graef SituationRheum ( View Tweet)
Nov 10, 2020
"The goal of a vaccine is not just to protect a (vaccinated) individual, but to end the pandemic." Dr. Dan Barouch #ACR20 @RheumNow

Dr. Rachel Tate uptoTate ( View Tweet)

Nov 09, 2020
Interesting Swedish abstract 1997 at #ACR20. Adjuvant #herpeszoster vaccine (Shingrix) not effective for 25% of JAKi-treated RA pts (n=40) for antibody response (T cell response usually worse, not reported). Is better than nothing good enough? Maybe we need to hold JAKi briefly?

Jeffrey Curtis RADoctor ( View Tweet)

Nov 09, 2020
Just watched David Beck’s talk on somatic mutations in VEXAS. Genotyping to link phenotypically diverse disease. Such an exciting strategy to identify additional unknown diseases!!! #ACR https://t.co/gU9HEZyjRP
Adam J Brown AdamJBrownMD ( View Tweet)
Nov 09, 2020
Prelim. results: Immunogenicity of adjuvanted #HerpesZoster subunit #vaccine in #RheumatoidArthritis patients taking #JAKinhibitors - Most RA pts on JAKi have sufficient antibody response to HZ vaccine - Acceptable safety profile Abs#1997 #ACR20 @RheumNow https://t.co/8HWAIwOATD

Mrinalini Dey DrMiniDey ( View Tweet)

Nov 09, 2020
Just a reminder: inflammatory arthritis irAEs can occur at almost any time after immune checkpoint inhibitor cancer immunotherapy is commenced. @LoyolaChicago #ACR20 ABST1566 @RheumNow https://t.co/qdEpNpzdNs
David Liew drdavidliew ( View Tweet)
Nov 09, 2020
Dr Kaellmark reports on immunogenicity of adjuvant herpes zoster subunit vaccine in RA patients treated with JAKi. 40 RA patients and 20 controls. Satisfactory serological responses and tolerability seen. @rheumnow #ACR20 Abstr#1997 https://t.co/UlDe4NllU0
Richard Conway RichardPAConway ( View Tweet)
Nov 09, 2020
×